Sphingolipids are a highly diverse category of compounds that serve not only as components of biologic structures but also as regulators of numerous cell functions. Because so many of the structural features of sphingolipids influence their biological activity, there is a need for comprehensive methods for quantitation of as many individual subspecies as possible. This dissertation describes methods that have been developed and validated for the extraction, liquid chromatographic separation, identification and quantitation of sphingolipids by electrospray ionization (ESI), tandem mass spectrometry (MS/MS) using an internal standard cocktail developed by the LIPID MAPS Consortium. The compounds that can be readily analyzed are sphingoid bases and sphingoid base 1-phosphates, as well as more complex species such as ceramides, ceramide 1-phosphates, sphingomyelins, and mono- and di-hexosylceramides. For broader utility, the methods have been optimized for two categories of tandem mass spectrometers. With minor modifications, these methods can be applied to the analysis of isomers such as glucosylceramide and galactosylceramide, and with the availability of additional internal standards, more complex species such as sulfatides can also be quantified. Using these methods 46 species of these compounds have been quantified in RAW264.7 cells, a macrophage cell line. Quantitation of individual sphingolipid metabolites is possible using liquid chromatography, tandem mass spectrometry, and stable isotope labeling with [13C]palmitic acid can be used to differentiate between metabolites produced by de novo synthesis versus turnover. This approach is more accurate when one knows the isotope enrichment of the precursor pool (in this case, [13C]-palmitoyl-CoA); therefore this dissertation describes methods to analyze both the various isotopic forms of palmitoyl-CoA and sphingolipids through sphingomyelins and monohexosylceramides using two cell models, HEK293 cells and RAW264.7 cells treated with Kdo2-Lipid A. The sphingolipid analysis was simplified by the fragmentation of most of the metabolites to backbone product ions. For example the presence of the isotopic label in the long chain base, N-acyl linked fatty acid, or both was determined via, m/z 264 for [12C]sphingosine (d18:1) and m/z 280 for [13C]sphingosine (m+16, d18:1), versus the m/z of the isotopically labeled precursor, (m+16 versus m+32).

No description available.

Το Vaccinium corymbosum (Ericaceae) είναι ένας ψηλός θάμνος, ο οποίος καλλιεργείται σε περιοχές της Αμερικής και της Ευρώπης για τους υψηλής διατροφικής αξίας καρπούς του (κυανά μύρτιλλα: blueberries). Στη χώρα μας, καλλιέργεια μύρτιλλων γίνεται κυρίως στην περιοχή της Δράμας. Οι περισσότερες μελέτες εστιάζουν στην ανάλυση των συστατικών των καρπών, ενώ η φυτοχημική σύσταση των φύλλων δεν έχει μελετηθεί εκτενώς. Η παρούσα εργασία, στόχο είχε την ανάλυση των κυριότερων φαινολικών συστατικών των φύλλων του φυτού, με χρήση χρωματογραφικών μεθόδων ανάλυσης. Τα αποξηραμένα φύλλα, τα οποία χρησιμοποιήθηκαν στην παρούσα διατριβή, προέρχονται από τις ποικιλίες ‘Bluecrop’ και ‘Patriot’, βιολογικής καλλιέργειας στην περιοχή της Δράμας. Προετοιμάστηκε αφέψημα των αποξηραμένων φύλλων, το οποίο στη συνέχεια εκχυλίστηκε διαδοχικά, με οξικό αιθυλεστέρα (AcOEt) και βουτανόλη (BuOH). Κατόπιν και με σκοπό τον εύκολο προσδιορισμό των φαινολικών ενώσεων, πραγματοποιήθηκε όξινη υδρόλυση (90 oC, 2 h, 50% μεθανόλη) όλων των κλασμάτων: Crude (αφέψημα), AcOEt, BuOH και Aqueous. Η ανάλυση των συστατικών πραγματοποιήθηκε με Υγρή Χρωματογραφία Υψηλής Απόδοσης με Ανιχνευτή Συστοιχίας Φωτοδιόδων (HPLC-DAD) και ύστερα με Υγρή Χρωματογραφία Υπερυψηλής Απόδοσης (UPLC-MS) με Φασματόμετρο Μάζας, το οποίο διαθέτει υβριδικό αναλυτή τετραπόλου – χρόνου πτήσης (Q-TOF). Για την HPLC-DAD ανάλυση χρησιμοποιήθηκε στήλη αντίστροφης φάσης (Luna C-18), με σύστημα βαθμιδωτής έκλουσης με τρείς διαλύτες: διάλυμα οξικού αμμωνίου (CH3COONH4-10 mM), ακετονιτρίλιο και μεθανόλη (Μαργιάννη, 2011). Επιπλέον, για την ποσοτικοποίηση των κυριότερων φαινολικών συστατικών χρησιμοποιήθηκε σύστημα βαθμιδωτής έκλουσης με δύο διαλύτες: διάλυμα CH3COONH4-10 mM και ακετονιτρίλιο (τροποποίηση Tsao et al., 2003). Στην ανάλυση UPLC-ESI-MS χρησιμοποιήθηκε στήλη αντίστροφης φάσης (BEH C18), με σύστημα βαθμιδωτής έκλουσης με δύο διαλύτες: 0.1% μυρμηκικό οξύ σε H2O και ακετονιτρίλιο. Τα αποτελέσματα έδειξαν, αρχικά, ότι κανένα από τα κλάσματα δεν περιέχει ανθοκυανίνες, ενώ το AcOEt κλάσμα είναι περισσότερο εμπλουτισμένο σε φαινολικά συστατικά, σε σχέση με τα άλλα κλάσματα. Με χρήση της UPLC-ESI-MS ανάλυσης, προσδιορίσθηκαν διάφορα συστατικά μεταξύ των οποίων φαινολικά οξέα και φλαβονοειδή. Ενδιαφέρον παρουσίασε το γεγονός ότι το Aqueous κλάσμα περιείχε μόνο φαινολικά οξέα. Η επιλογή της μεθόδου της όξινης υδρόλυσης, φαίνεται να ήταν ικανοποιητική, αφού τα άγλυκα τμήματα των γλυκοζυλιωμένων φλαβονολών, αλλά και τα προϊόντα διάσπασης του εστερικού δεσμού του χλωρογενικού οξέος, προσδιορίσθηκαν εύκολα με την UPLC-ESI-MS ανάλυση. Στα επιμέρους δείγματα ποσοτικοποιήθηκαν, με χρήση HPLC-DAD ανάλυσης τα εξής φαινολικά συστατικά: χλωρογενικό οξύ, ρουτίνη, υπεροζίτης, ισοκερσιτρίνη και κερκετίνη. Συνεπώς, το αφέψημα των καλλιεργούμενων μύρτιλλων είναι μία καλή πηγή φαινολικών συστατικών. / Vaccinium corymbosum (Ericaceae) is a tall shrub, which is cultivated in parts of America and Europe for their fruits (blueberries), which possess high nutritional value. In our country, blueberries are mainly cultivated in the area of Drama. Many studies focus on the analysis of the constituents of fruits, while the phytochemical composition of leaves has not been studied in detail. The present study aimed the analysis of the main components of blueberry leaves, using chromatographic techniques. Dried leaves (var ‘Bluecrop’ and ‘Patriot’) were obtained from the Cooperative ‘‘Biodrama’’. The decoction of dried leaves was prepared and then extracted sequentially with ethyl acetate and butanol. In order to easily identify the phenolic compounds, all fractions (Crude or decoction, AcOEt, BuOH and Aqueous) were hydrolysed in acid conditions (90 oC, 2 h, 50% MeOH). The components of the fractions were analyzed firstly by High Performance Liquid Chromatography with Diode Array Detector (HPLC-DAD) and then with Ultra High Performance Liquid Chromatography (UPLC-MS) with Mass Spectrometry. The mass spectrometer features hybrid quadrupole - time of flight (Q-TOF) analyzer. For the HPLC-DAD analysis a reverse phase column (Luna C-18) was used with a gradient elution system with three solvents: ammonium acetate (CH3COONH4-10 mM), acetonitrile (AcCN) and methanol (MeOH) (Margianni, 2011). Moreover, the quantification of the major phenolic components system was done with a gradient elution system of CH3COONH4-10 mM and AcCN (modified from Tsao et al., 2003). UPLC-ESI-MS was performed on a reverse phase column (BEH C18) with a gradient elution system with two solvents: 0.1% formic acid in H2O and AcCN. Firstly, the results showed that none of the fractions contain anthocyanins while AcOEt fraction is more enriched in phenolic compounds, in comparison to the other fractions. Using UPLC-ESI-MS analysis, we identified several components including phenolic acids and various flavonoids. Interestingly, the Aqueous fraction contained only phenolic acids. The choice of the method of acid hydrolysis appears to be satisfactory for identification purposes, since the aglycones of glycosylated flavonols, and the cleavage products of the chlorogenic acid, was determined easily by UPLC-ESI-MS analysis. The phenolic compounds: chlorogenic acid, rutin, hyperoside, isoquercitrin and quercetin were quantified in blueberry leaf decoction using HPLC-DAD. Therefore, the decoction of cultivated blueberries is a good source of phenolic compounds.

Die Verwendung anthropogener organischer Spurenstoffe wie beispielsweise Pharmazeutika, Lifestyle-Produkte, Biozide und Pestizide als Indikatoren für die Bewertung der Wasserqualität hat großes Interesse in der Wissenschaftsgemeinde geweckt, und die Verwendung dieser Substanzen als Indikatoren für die Prozessoptimierung, Quellzuordnung und zur Abschätzung des Ausmaßes einer möglichen Kontamination (z. B. den Abwasseranteil von Oberflächen- und Grundwasser) besitzt ein sehr großes Anwendungspotential. Die hier präsentierte Arbeit ist die erfolgreiche und konsequente Weiterführung bestehender Forschungsaktivitäten zur Eignung ausgewählter Spurenstoffe als Indikatoren für die Bewertung der Wasserqualität, ihrem Vorkommen und Verhalten in der Umwelt sowie ihrer Redox-spezifischen Transformation. Um eine Substanz als Indikator verwenden zu können, müssen sensitive und selektive Analysenmethoden verfügbar sein. In der vorliegenden Arbeit wird die Entwicklung einer Multimethode für den Nachweis von 46 basischen, neutralen und sauren Analyten mittels der Hochleistungs-Flüssigchromatographie und Elektronenspray-Ionisation (ESI) mit anschließender Tandem-Massenspektrometrie (HPLC-ESI-MS/MS) beschrieben. Das ausgewählte Analytenspektrum deckt einen weiten Bereich hinsichtlich der Polarität der Stoffe (log Kow <0–5,9) sowie ihrer repräsentierten Kontaminationsquellen ab. Die Besonderheit der entwickelten Methode stellt die simultane Festphasenanreicherung (SPE), Trennung und Detektion aller Analyten dar. Um dieses realisieren zu können, wird das ESI-Interface in beiden möglichen Operationsmodi (+/−) verwendet, so dass pro Probe nur eine Injektion notwendig ist. Die Bestimmungsgrenzen der Methode in Fluss- und Meerwasser liegen im Bereich weniger ng/L. Im weiteren Verlauf der Arbeit wird die hohe Flexibilität der Methode (Integration zusätzlicher Analyten und Anpassung an andere Wassertypen) demonstriert. Im darauf folgenden Abschnitt werden die Ergebnisse eines intensiven Fluss-Monitorings vorgestellt. Der Fokus liegt dabei auf der Korrelation von 41 Spurenstoffen mit Kalium (K+) und deren räumlichen und zeitlichen Varianz. Da Urin je nach K+-Hintergrundkonzentration des Gewässers eine signifikante K+-Quelle darstellen kann, ist in Gewässern mit hohem Abwasseranteil eine positive Korrelation von abwasserbürtigen Stoffen und K+ zu erwarten. Diese Korrelation ist für Stoffe mit folgenden Charakteristika bestätigt worden: 1) Kläranlagenabläufe sind die Hauptquelle der Substanz; 2) Die Fracht der Substanz in der Kläranlage ist nur geringen zeitlichen Schwankungen unterworfen; und 3) Hohe Persistenz der Verbindung bei der Abwasserbehandlung und in der Umwelt. Neben anderen Spurenstoffen zeigen Carbamazepin, Sulfamethoxazol und Tolyltriazol die beste Korrelation. Darüber hinaus sind die K+-Äquivalente der einzelnen Stoffe offensichtlich abhängig von Landnutzung und Bevölkerungsstruktur im Einzugsgebiet des untersuchten Flussabschnitts. Eine Korrelation mit K+ zeigt, dass die Konzentration des korrelierenden Spurenstoffs nur vom Abfluss des Fließgewässers abhängig ist. Nach diesem Konzept könnte die Vorhersage der Konzentration entsprechender Spurenstoffe an bestimmten Flussabschnitten erheblich vereinfacht werden. Analog zu den genannten Charakteristika 1–3 kann der Ansatz zur Quellidentifizierung neu auftretender/identifizierter Substanzen genutzt werden. Darüber hinaus könnten Eintragsfunktionen für die korrelierenden Spurenstoffe hinsichtlich Oberflächenwasser/Grundwasser-Interaktion hergeleitet werden. Dies würde eine realistischere Bewertung der Reinigungsleistung von Anlagen zur (künstlichen) Grundwasseranreicherung ermöglichen. Anschließend wird eine Methode präsentiert, mit Hilfe derer sich das Volumen von schnell transportiertem, unbehandeltem Abwasser in einem Karstaquifer abschätzen lässt. Eine Kontamination mit unbehandeltem Abwasser und die damit verbundene bakterielle Belastung stellen eine ernsthafte Bedrohung für die Trinkwasserqualität und die öffentliche Gesundheit dar. Das Ausmaß einer Kontamination quantifizieren zu können ist allerdings meist problematisch. Daher wurde ein bereits bekannter Massenbilanzansatz der aktuellen Fragestellung angepasst. In die Berechnung der Abwassermenge fließen ein: Die Coffein-Fracht an der Quelle, die übliche Coffein-Belastung in unbehandeltem Abwasser und der tägliche durchschnittliche Trinkwasserverbrauch pro Person im beobachteten Quelleinzugsgebiet. Der entwickelte Ansatz wurde zur Berechnung der täglich zuströmenden Abwassermenge an einem bereits gut charakterisierten Karstaquifer (Gallusquelle, Deutschland) angewendet. Weiterhin werden die Ergebnisse einer Mikrokosmos-Studie zur Transformation des Antibiotikums Sulfamethoxazol (SMX) unter denitrifizierenden Bedingungen vorgestellt. Ein selektiver Reaktionsmechanismus mit den unter denitrifizierenden Bedingungen gebildeten N-Spezies Stickstoffmonoxid (NO) und Nitrit (NO2−) ist die zugrunde liegende Arbeitshypothese und die Bildung der daraus abgeleiteten Transformationsprodukte (TP) 4-Nitro-N-(5-methylisoxazol-3-yl)-benzenesulfonamid (4-Nitro-SMX) und N-(5-methylisoxazol-3-yl)-benzenesulfonamid (Desamino-SMX) während des zeitlichen Verlaufs eines Wasser/Sediment-Batchversuchs wird dargestellt. Beide TPs können auch in Umweltproben nachgewiesen werden. Unter geeigneten Reaktionsbedingungen kann das TP 4-Nitro-SMX zudem zu SMX retransformiert werden. Dies zeigt die hohe Relevanz der vorliegenden Arbeit hinsichtlich des Vorkommens und Verhaltens dieses Antibiotikums in der Umwelt und für das Monitoring der Wasserqualität. Darüber hinaus können Redox-spezifische TPs als Indikatoren für den reaktiven Stofftransport verwendet werden.

Neurodegenerative diseases have been shown to correlate positively with an ageing population. The most common neurodegenerative diseases are amyotrophic lateral sclerosis (ALS), Parkinson’s disease and Alzheimer’s disease. The cause of these diseases is believed to be the interaction between genetic and environmental factors, synergistically acting with ageing. BMAA (β-methylamino-L-alanine) is one kind of toxin present in our environment and might play an important role in the development of those diseases. BMAA was initially isolated from cycad seeds in Guam, where the incidence of ALS/Parkinsonism-dementia complex among the indigenous people was 50 – 100 times higher than the rest of the world in the 1950’s. BMAA can induce toxic effects on rodents and primates. Furthermore, it can potentiate neuronal injury on cell cultures at concentrations as low as 10 µM. BMAA was reported to be produced by cyanobacteria, and could bio-magnify through the food chain. In this thesis, work was initially focused on the improvement of an existing analytical method for BMAA identification and quantification using liquid chromatography coupled with tandem mass spectrometry.  Subsequently, the refined method was applied to environmental samples for probing alternative BMAA producer(s) in nature and to seafood samples for estimation of human exposure to this toxin. In Paper I, a systematic screening of the isomers of BMAA in a database was performed and seven potential isomers were suggested. Three of them were detected or suspected in natural samples. In Paper II, a deuterated internal standard was synthesized and used for quantifying BMAA in cyanobacteria. In Paper III, Diatoms were discovered to be a BMAA producer in nature. In Paper IV, ten popular species of seafood sold in Swedish markets were screened for BMAA. Half of them were found to contain BMAA at a level of 0.01 – 0.90 µg/g wet weight. In Future perspectives, the remaining questions important in this field are raised.

Vemurafenib is a potent serine/threonine kinase inhibitor and is registered as Zelboraf® for the treatment of metastatic melanomas harboring BRAFV600E mutations. There is a large individual variation in drug response and the side effects observed among patients treated with Zelboraf® has proven to be severe.  LC-MS/MS methods were developed to measure vemurafenib and its metabolites in human plasma for prediction of treatment outcome and side effects in order to individualize treatment with Zelboraf®.  A novel, rapid quantification method was developed for vemurafenib using a stable isotope labeled internal standard. The method was validated according to international guidelines with regard to calibration range, accuracy, precision, carry-over, dilution integrity, selectivity, matrix effects, recovery and stability. All parameters met the set acceptance criteria.  The first method suitable for quantifying vemurafenib metabolites in human plasma is presented. Lacking commercially available reference substances, human liver microsomes were used to produce the metabolites. In patient samples at steady-state five previously in vitro identified metabolites were quantified for the first time.

Malaria is currently one of the most imperative parasitic diseases in developing countries. Artesunate has a short half-life, low aqueous solubility and resultant poor and erratic absorption upon oral administration, which translate to low bioavailability. Mefloquine is eliminated slowly with a terminal elimination half-life of approximately 20 days and has neuropsychiatric side effects. Novel drug delivery systems have been utilised to optimise chemotherapy with currently available antimalarial drugs. Pheroid™ technology is a patented drug delivery system which has the ability to capture, transport and deliver pharmaceutical compounds. Pheroid™ technology may play a key role in ensuring effective delivery and enhanced bioavailability of novel antimalarial drugs. The aim of this study was to evaluate the possible efficacy and bioavailability enhancement of the selected antimalarial drugs, artesunate and mefloquine, in combination with Pheroid™ vesicles. The in vitro efficacy of artesunate and mefloquine co-formulated in the oil phase of Pheroid™ vesicles and entrapped in Pheroid™ vesicles 24 hours after manufacturing were investigated against a 3D7 chloroquine-sensitive strain of Plasmodium falciparum. Parasitemia (%) was quantified with flow cytometry after incubation periods of 48 and 72 hours. Drug sensitivity was expressed as 50% inhibitory concentration (IC50) values. An in vivo bioavailability study with artesunate and mefloquine was also conducted in combination with Pheroid™ vesicles, using a mouse model. A sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to analyse the drug levels. C57 BL6 mice were used during this study. The selected antimalarial drugs were administered at a dose of 20 mg/kg with an oral gavage tube. Blood samples were collected by means of tail bleeding. The in vitro drug sensitivity assays revealed that artesunate, co-formulated in the oil phase of Pheroid™ vesicles and evaluated after a 48 hour incubation period, decreased the IC50 concentration significantly by 90%. Extending the incubation period to 72 hours decreased the IC50 concentration of artesunate, also co-formulated in the oil phase of Pheroid ™ vesicles significantly by 72%. No statistically significant differences between the reference and Pheroid™ vesicle groups were achieved when artesunate was entrapped 24 hours after manufacturing of Pheroid™ vesicles. Mefloquine co-formulated in the oil phase of Pheroid™ vesicles and evaluated after a 48 hour incubation period decreased the IC50 concentration by 36%. Extending the incubation period to 72 hours increased the efficacy of the Pheroid™ vesicles and the IC50 concentration was significantly decreased by 51%. In contrast with the results obtained with artesunate, entrapment of mefloquine in Pheroid™ vesicles 24 hours after manufacturing decreased the IC50 concentration significantly by 66%. The LC-MS/MS method was found to be sensitive, selective and accurate for the determination of artesunate and its active metabolite, dihydroartemisinin (DHA) in mouse plasma and mefloquine in mouse whole blood. Most of the artesunate plasma concentrations were below the limit of quantification in the reference group and relatively high outliers were observed in some of the samples. The mean artesunate levels of the Pheroid™ vesicle group were lower compared to the reference group, but the variation within the Pheroid™ vesicle group lessened significantly. The mean DHA concentrations of the Pheroid™ vesicle group were significantly higher. DHA obtained a higher peak plasma drug concentration with the Pheroid™ vesicle group (173.0 ng/ml) in relation to the reference group (105.0 ng/ml) and at a much faster time (10 minutes in Pheroid™ vesicles in contrast to 30 minutes of the reference group). Pharmacokinetic models could not be constructed due to blood sampling per animal limitation. The incorporation of mefloquine in Pheroid™ vesicles did not seem to have improved results in relation to the reference group. No statistical significant differences were observed in the pharmacokinetic parameters between the two groups. The relative bioavailability (%) of the Pheroid™ vesicle incorporated mefloquine was 7% less bioavailable than the reference group. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2010.

No description available.

Anatoxin-a (ANTX) is a neurotoxin produced by several freshwater cyanobacteria and has been implicated in the death of livestock and domestic animals from consumption of tainted surface waters. ANTX is unstable under normal conditions and is somewhat problematic to extract and study. Accelerated solvent extraction (ASE) combined with liquid chromatography-mass spectrometry (LC/MS) was used to develop an efficient extraction and analytical method for both ANTX and the more commonly encountered hepatotoxic microcystins produced by cyanobacteria. The effects of nitrogen supply on the cellular production and release of ANTX was investigated in Aphanizomenon issatschenkoi (Ussaczew) Proschkina-Lavrenko (Nostocales). In contrast to the predictions of the carbonnutrient balance hypothesis, the maximum production was observed under moderate N stress. In addition, steady state fugacity-based models were employed to investigate ANTX’s distribution and fate in freshwater ecosytems. ANTX was not found to be very persistent in aquatic ecosystems and did not appear to bioaccumulate in fish, at least not from the dissolved phase.

Malaria is currently one of the most imperative parasitic diseases in developing countries. Artesunate has a short half-life, low aqueous solubility and resultant poor and erratic absorption upon oral administration, which translate to low bioavailability. Mefloquine is eliminated slowly with a terminal elimination half-life of approximately 20 days and has neuropsychiatric side effects. Novel drug delivery systems have been utilised to optimise chemotherapy with currently available antimalarial drugs. Pheroid™ technology is a patented drug delivery system which has the ability to capture, transport and deliver pharmaceutical compounds. Pheroid™ technology may play a key role in ensuring effective delivery and enhanced bioavailability of novel antimalarial drugs. The aim of this study was to evaluate the possible efficacy and bioavailability enhancement of the selected antimalarial drugs, artesunate and mefloquine, in combination with Pheroid™ vesicles. The in vitro efficacy of artesunate and mefloquine co-formulated in the oil phase of Pheroid™ vesicles and entrapped in Pheroid™ vesicles 24 hours after manufacturing were investigated against a 3D7 chloroquine-sensitive strain of Plasmodium falciparum. Parasitemia (%) was quantified with flow cytometry after incubation periods of 48 and 72 hours. Drug sensitivity was expressed as 50% inhibitory concentration (IC50) values. An in vivo bioavailability study with artesunate and mefloquine was also conducted in combination with Pheroid™ vesicles, using a mouse model. A sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to analyse the drug levels. C57 BL6 mice were used during this study. The selected antimalarial drugs were administered at a dose of 20 mg/kg with an oral gavage tube. Blood samples were collected by means of tail bleeding. The in vitro drug sensitivity assays revealed that artesunate, co-formulated in the oil phase of Pheroid™ vesicles and evaluated after a 48 hour incubation period, decreased the IC50 concentration significantly by 90%. Extending the incubation period to 72 hours decreased the IC50 concentration of artesunate, also co-formulated in the oil phase of Pheroid ™ vesicles significantly by 72%. No statistically significant differences between the reference and Pheroid™ vesicle groups were achieved when artesunate was entrapped 24 hours after manufacturing of Pheroid™ vesicles. Mefloquine co-formulated in the oil phase of Pheroid™ vesicles and evaluated after a 48 hour incubation period decreased the IC50 concentration by 36%. Extending the incubation period to 72 hours increased the efficacy of the Pheroid™ vesicles and the IC50 concentration was significantly decreased by 51%. In contrast with the results obtained with artesunate, entrapment of mefloquine in Pheroid™ vesicles 24 hours after manufacturing decreased the IC50 concentration significantly by 66%. The LC-MS/MS method was found to be sensitive, selective and accurate for the determination of artesunate and its active metabolite, dihydroartemisinin (DHA) in mouse plasma and mefloquine in mouse whole blood. Most of the artesunate plasma concentrations were below the limit of quantification in the reference group and relatively high outliers were observed in some of the samples. The mean artesunate levels of the Pheroid™ vesicle group were lower compared to the reference group, but the variation within the Pheroid™ vesicle group lessened significantly. The mean DHA concentrations of the Pheroid™ vesicle group were significantly higher. DHA obtained a higher peak plasma drug concentration with the Pheroid™ vesicle group (173.0 ng/ml) in relation to the reference group (105.0 ng/ml) and at a much faster time (10 minutes in Pheroid™ vesicles in contrast to 30 minutes of the reference group). Pharmacokinetic models could not be constructed due to blood sampling per animal limitation. The incorporation of mefloquine in Pheroid™ vesicles did not seem to have improved results in relation to the reference group. No statistical significant differences were observed in the pharmacokinetic parameters between the two groups. The relative bioavailability (%) of the Pheroid™ vesicle incorporated mefloquine was 7% less bioavailable than the reference group. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2010.